Nemaura Medical to Present at Virtual Diabetes Technology Meeting 2020
October 22 2020 - 8:00AM
Nemaura Medical, Inc. (NASDAQ: NMRD)(“Nemaura” or the “Company”), a
medical technology company focused on developing and
commercializing non-invasive wearable diagnostic devices and
supporting personalized lifestyle coaching programs, today
announces that it will present on Day 1 of the Virtual Diabetes
Technology Meeting 2020 on November 12, 2020 at 2:50 PT. Nemaura’s
Chief Executive Officer Dr. Faz Chowdhury will give a presentation
titled “CGM Usage for the Management and Reversal of Type 2
diabetes.”
Due to the impact of COVID-19, the 20th Annual Diabetes
Technology Meeting will be held as a virtual event. The meeting’s
goal is to connect technology developers and users to facilitate
the creation of new and cost-effective tools to help people with
diabetes. FDA officials also participate in the meeting and will
update attendees on current U.S. regulatory policies. The sharing
of original data is particularly emphasized, too. The
format of the meeting will include state-of-the-art lectures, oral
presentations of abstracts, panel discussions with Q & A
sessions, and virtual poster sessions. Investors wishing to view
Dr. Chowdhury’s presentation can register for the meeting at
https://www.diabetestechnology.org/dtm/.
In December 2020 in the U.S., Nemaura plans to launch proBEAT™,
a non-invasive, wearable, glucose monitor which is expected to help
users improve their knowledge of how a range of lifestyle, dietary
and health and wellbeing factors impact their sugar levels by
acting like a black box flight recorder. Big data about the
multitude of factors that affect glucose levels will be gathered
and used to provide artificial intelligence based feedback and
prompts. This will be combined with a behavioral change and
weight management digital app in-licensed from Healthimation Inc.
and is expected to collectively help diabetic and pre-diabetic
patients better manage, reverse, or prevent the onset of
diabetes. In the U.S., there are currently 88 million
patients considered to be pre-diabetic and 25 million patients with
Type 2 diabetes. Worldwide, there are 420 million patients with
diabetes and over 1 billion people considered
pre-diabetic.About Nemaura Medical, Inc.
Nemaura Medical Inc. is a medical technology company developing
and commercializing non-invasive wearable diagnostic devices. The
company is currently commercializing sugarBEAT® and proBEAT™.
sugarBEAT®, a CE mark approved Class IIb medical device, is a
non-invasive and flexible continuous glucose monitor (CGM)
providing actionable insights derived from real time glucose
measurements and daily glucose trend data, which may help people
with diabetes and pre-diabetes to better manage, reverse, and
prevent the onset of diabetes. Nemaura has submitted a PMA
(Premarket Approval Application) for sugarBEAT® to the U.S. FDA.
proBEAT™ combines non-invasive glucose data processed using
artificial intelligence and a digital healthcare subscription
service and is expected to be launched in the U.S. as a general
wellness product.
The Company sits at the intersection of the global Type 2
diabetes market that is expected to reach nearly $59 billion by
2025, the $50+ billion pre-diabetic market, and the wearable
health-tech sector for weight loss and wellness applications that
is estimated to reach $60 billion by 2023.
For more information, please visit www.NemauraMedical.com.
Cautionary Statement Regarding Forward-Looking
Statements:
The statements in this press release that are not historical
facts may constitute forward-looking statements that are based on
current expectations and are subject to risks and uncertainties
that could cause actual future results to differ materially from
those expressed or implied by such statements. Those risks and
uncertainties include, but are not limited to, the launch of
proBEAT™ in the US, risks related to regulatory status and the
failure of future development and preliminary marketing efforts,
Nemaura’s ability to secure additional commercial partnering
arrangements, risks and uncertainties relating to Nemaura and its
partners’ ability to develop, market and sell proBEAT™, the
availability of substantial additional equity or debt capital to
support its research, development and product commercialization
activities, and the success of its research, development,
regulatory approval, marketing and distribution plans and
strategies, including those plans and strategies related to both
proBEAT™ digital health, and sugarBEAT®. There can be no assurance
that the company will be able to reach a part of or any of the
global market for CGM with its products/services. The FDA reserves
the right to re-evaluate their decision that proBEAT™ qualifies as
a general wellness product should it become aware of any issues
such as skin irritation or other adverse events from the device, as
well as any misuse impacting patient safety, and any other reason
as the FDA may see fit at its discretion to determine the product
does not fit the definition of a general wellness product. These
and other risks and uncertainties are identified and described in
more detail in Nemaura’s filings with the United States Securities
and Exchange Commission, including, without limitation, its Annual
Report on Form 10-K for the most recently completed fiscal year,
its Quarterly Reports on Form 10-Q, and its Current Reports on Form
8-K. Nemaura undertakes no obligation to publicly update or revise
any forward-looking statements.
Contact:
Jules AbrahamCORE IR917-885-7378julesa@coreir.com
Nemaura Medical (NASDAQ:NMRD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Nemaura Medical (NASDAQ:NMRD)
Historical Stock Chart
From Apr 2023 to Apr 2024